Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALKS 
Alkermes Plc (ALKS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ALKS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $41.07
1 Year Target Price $41.07
| 8 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.17% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.76B USD | Price to earnings Ratio 13.74 | 1Y Target Price 41.07 |
Price to earnings Ratio 13.74 | 1Y Target Price 41.07 | ||
Volume (30-day avg) 15 | Beta 0.42 | 52 Weeks Range 22.90 - 36.45 | Updated Date 07/4/2025 |
52 Weeks Range 22.90 - 36.45 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 23.3% | Operating Margin (TTM) 4.5% |
Management Effectiveness
Return on Assets (TTM) 11.62% | Return on Equity (TTM) 25.71% |
Valuation
Trailing PE 13.74 | Forward PE 20 | Enterprise Value 3947487072 | Price to Sales(TTM) 3.14 |
Enterprise Value 3947487072 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 2.61 | Enterprise Value to EBITDA 8.46 | Shares Outstanding 164900992 | Shares Floating 162239778 |
Shares Outstanding 164900992 | Shares Floating 162239778 | ||
Percent Insiders 1.49 | Percent Institutions 106.94 |
Upturn AI SWOT
Alkermes Plc
Company Overview
History and Background
Alkermes was founded in 1987 as a drug delivery company. It evolved into a fully integrated biopharmaceutical company focusing on developing and commercializing innovative medicines for central nervous system (CNS) diseases and cancer.
Core Business Areas
- CNS Products: Development and commercialization of products for schizophrenia, bipolar disorder, depression, and alcohol dependence. This segment includes proprietary and partnered products.
- Oncology: Research and development of new cancer treatments, particularly those focused on immune-oncology. This is a growing area for Alkermes.
- Royalty and Manufacturing Revenues: Revenues from partnered products where Alkermes receives royalties or provides manufacturing services.
Leadership and Structure
The leadership team includes Richard Pops (CEO). The organizational structure includes research and development, commercial operations, and manufacturing departments.
Top Products and Market Share
Key Offerings
- VIVITROL: An injectable, extended-release form of naltrexone for the treatment of alcohol dependence and opioid dependence. VIVITROL holds a significant portion of the market for injectable naltrexone products. Competitors include oral naltrexone and other treatments for substance abuse.
- market_share: 40%
- users: Estimated 100,000 patients
- ARISTADA: An injectable, extended-release atypical antipsychotic for the treatment of schizophrenia. Aristada competes with other long-acting injectables like Invega Sustenna (JNJ), Risperdal Consta (JNJ) and Abilify Maintena (OTCPK:BMY).
- market_share: 7%
- revenue: around 300M
- LYBALVI: Oral treatment for schizophrenia and bipolar I disorder. LYBALVI competes with other oral antipsychotics, with a focus on a differentiated profile (lower weight gain). Competitors include olanzapine.
- market_share: Emerging (still launching).
- revenue: still emerging
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high research and development costs, and strict regulatory oversight. Focus on CNS disorders is a high-need, high-reward area.
Positioning
Alkermes is positioned as a specialty pharmaceutical company focused on CNS diseases and oncology. It has a portfolio of proprietary and partnered products and a focus on innovative drug delivery technologies.
Total Addressable Market (TAM)
The TAM for CNS disorders is estimated to be in the billions of dollars globally. Alkermes targets specific segments within this market. Oncology TAM is also significant, expected to grow with cancer rates and drug innovations.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities in CNS disorders
- Proprietary drug delivery technologies
- Established commercial infrastructure
- Partnerships with major pharmaceutical companies
- Established products with recurring revenue
Weaknesses
- Reliance on a limited number of key products
- Potential for generic competition
- High R&D expenses
- Regulatory risks
Opportunities
- Expanding product pipeline in CNS and oncology
- Acquiring complementary technologies or products
- Expanding into new geographic markets
- Partnerships for commercialization
Threats
- Competition from other pharmaceutical companies
- Pricing pressures from payers
- Regulatory changes
- Patent expirations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- TEVA
- RDHL
- LUNR
Competitive Landscape
Alkermes' advantages include its proprietary drug delivery technologies and focus on CNS disorders. Disadvantages include its reliance on a limited number of key products and competition from larger pharmaceutical companies.
Major Acquisitions
Rodin Therapeutics
- Year: 2019
- Acquisition Price (USD millions): 100
- Strategic Rationale: Acquired Rodin Therapeutics to expand its neuroscience pipeline with novel therapies targeting synaptic function for cognitive disorders.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would need to be analyzed based on past financial performance, focusing on revenue growth, product sales, and R&D investments.
Future Projections: Future growth projections would be based on analyst estimates, which would factor in product pipeline progress, market trends, and competitive dynamics.
Recent Initiatives: Recent strategic initiatives include pipeline advancements, regulatory submissions for new drugs, and commercial expansion of existing products.
Summary
Alkermes is a specialty pharmaceutical company with a focus on CNS disorders and oncology. VIVITROL and ARISTADA are key revenue drivers, but the company faces competition and regulatory risks. The company's pipeline and potential acquisitions could drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), company press releases, investor presentations, analyst reports, market research reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alkermes Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1991-07-16 | Chairman & CEO Mr. Richard F. Pops | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1800 | Website https://www.alkermes.com |
Full time employees 1800 | Website https://www.alkermes.com | ||
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.